Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 15/20 | 0.55 |
| ▸ | CES1 | P23141 | 13/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280150 | 0.81 | MAPT (0.54) | CES2CES1ALDH1A1HTTCPA1 | |
| Hydrochloric Acid SCHEMBL27286730 | 0.79 | MAPT (0.52) | CES2CES1ALDH1A1HTTCPA1 | |
| SCHEMBL29875401 | 0.75 | ALDH1A1 (0.46) | CES2CES1ALDH1A1HTTCPA1 | |
| SCHEMBL1984045 | 0.75 | MAOA (0.44) | CES2CES1ALDH1A1HTTCPA1 | |
| SCHEMBL14141728 | 0.75 | CES2 (0.75) | CES2CES1ALDH1A1HTTLMNA | |
| SCHEMBL13875468 | 0.75 | CES1 (0.67) | CES2CES1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5682430 | 0.75 | MEN1 (0.57) | CES2CES1ALDH1A1HTTCPA1 | |
| SCHEMBL361897 | 0.74 | CES2 (0.59) | CES2CES1ALDH1A1 | |
| SCHEMBL28185548 | 0.73 | PRMT1 (0.43) | CES2CES1ALDH1A1HTTCPA1 | |
| SCHEMBL5318745 | 0.73 | CES2 (0.64) | CES2CES1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110757-A1 | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis | ARRHENIUS THOMAS (US) | 2004-06-10 | — | — | US | disclosed |
| EP-1370250-A2 | FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002076438-A2 | FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110757-A1 | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis | FLT1, FLT4, TEK | CES2 4224/4885CES1 1825/4885ALDH1A1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.